Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15(INK4b) and p16(INK4a) in human thyroid carcinoma cell lines and primary thyroid carcinomas

Cancer

Volumn 83, Issue 10, 1998, Pages 2185-2193

  Elisei, Rossella ^a   Shiohara, Masaaki ^b   Koeffler, H Phillip ^b   Fagin, James A ^a,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cell lines; CpG methylation; P15(INK4b); P16(INK4a); Thyroid carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P16;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; GENE MUTATION; HUMAN; HUMAN CELL; METHYLATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; THYROID CARCINOMA;

ADENOMA; BLOTTING, SOUTHERN; CARCINOMA, PAPILLARY; CARRIER PROTEINS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DNA METHYLATION; GENES, TUMOR SUPPRESSOR; HUMANS; POINT MUTATION; POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0032533645     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981115)83:10<2185::AID-CNCR18>3.0.CO;2-4     Document Type: Article

References (50)

1. Namba H, Matsuo K, Fagin JA. Cloual composition of benign and malignant human thyroid tumors. J Clin Invest 1990;86:120-5.
2. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993;365:649-51.
3. O'Sullivan C, Barton CM, Staddon SL, Brown CL, Lemoine NR. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinog 1991;4:345-9.
4. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA. H-Ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab 1990;71:223-9.
5. Suarez HG, du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990;5:565-70.
6. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989;4:159-64.
7. Matsuo K, Tang S, Zeki K, Gutman PA, Fagin JA. Aberrant deoxyribonucleic acid methylation in human thyroid tumors. J Clin Endocrinol Metab 1993;77:991-5.
8. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990;4:1474-9.
9. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63.
10. Bongarzone I, Pierotti MA, Monzini N, Mondellini P, Manenti G, Donghi R, et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989;4:1457-62.
11. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang S, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiatied human thyroid carcinomas. J Clin Invest 1993;91:179-84.
12. Donghi R, Longoni A, Pilotti S, Michieli P, Porta GD, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993;91:1753-60.
13. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369-71.
14. Hunter T, Pines J. Cyclins and cancer. Cell 1991;66:1071-4.
15. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995;86:841-54.
16. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, et al.. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994;265:415-6.
17. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995;11:210-2.
18. INK4 in human cancer. Proc Natl Acad Sci USA 1994;91: 11045-9.
19. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
20. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995;375:506-10.
21. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375:503-6.
22. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
23. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994;371:257-61.
24. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions 1f the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
25. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (Multiple Tumor Suppressor/Cyclin-dependent Kinase 4 Inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396-7.
26. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
27. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:22-6.
28. Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, et al. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res 1995;55:3421-3.
29. Giani C, Finocchiaro G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 1994;54:6338-9.
30. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54:6321-4.
31. INK4B/MTS2 genes in biliary tract cancers. Cancer Res 1995;55:2756-60.
32. Nakamaki T, Kawamata N, Schwaller J, Tobler A, Fey M, Pakkala S, et al. Structural integrity of the cyclin-dependent kinase inhibitor genes p15, p16 and p18 in myeloid leukaemias. Br J Haematol 1995;91:139-49.
33. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
34. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 1994;54:5269-72.
35. Gonzales-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4531-5.
36. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
37. Herman JG, Merlo A, Mao L, Lapidus R, Issa JJ, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
38. Singer-Sam J, Yang TP, Mori N, Tanguay RL, Le Bon JM, Flores JC, et al. DNA methylation in the 5′ region of the mouse PGK-1 gene and a quantitative PCR assay for methylation. In: Clawson GA, Willis DB, Weissbach A, Jones PA, editors. Nucleic Acid Methylation 1990;128:285-9.
39. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, et al. A novel cyclin encoded by a bcl-1-linked candidate oncogene. Nature 1991;350:512-5.
40. Hatta Y, Hirama T, Takeuchi S, Lee E, Pham E, Miller CW, et al. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol 1995;154:1954-7.
41. Jones CJ, Shaw JJ, Wyllie FS, Gaillard N, Schlumberger M, Wynford-Thomas D. High frequency deletion of the tumor suppressor gene p16 INK4a (MTS1) in human thyroid cancer cell lines. Mol Cell Endocrinol 1996;116:115-9.
42. Tung WS, Shevlin DW, Bartsch D, Norton JA, Wells SA, Goodfellow P. Infrequent CDKN2 mutation in human differentiated thyroid cancer. Mol Carcinog 1996;15:5-10.
43. Calabrò V, Strazzullo M, La Mantia G, Fedele M, Paulin C, Fusco A, et al. Status and expression of the p16INK4a gene in human tumors and thyroid-tumor cell lines. Int J Cancer 1996;67:29-34.
44. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 1995;86:1269-75.
45. ink4a tumor suppressor protein. Cancer Res 1995;55:2503-6.
46. INK4a and its interaction with CDK4. Biochem Biophys Res Comm 1996;218:254-9.
47. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 1995;85:2699-704.
48. Ink4a, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995;86:755-60.
49. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995;55:1448-51.
50. INK4) in human breast carcinomas. Cancer Res 1994;54:5262-4.